AQR Capital Management
AKBA icon

AQR Capital Management’s Akebia Therapeutics AKBA Stock Holding History

AQR Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Buy
9,151,524
+7,358,904
+411% +$8.76M ﹤0.01% 1553
2026
Q1 		$2.49M Buy
1,792,620
+1,145,941
+177% +$1.57M ﹤0.01% 2205
2025
Q4 		$1.04M Buy
646,679
+204,207
+46% +$428K ﹤0.01% 2528
2025
Q3 		$1.21M Buy
442,472
+16,523
+4% +$55K ﹤0.01% 2312
2025
Q2 		$1.55M Buy
425,949
+248,988
+141% +$684K ﹤0.01% 1938
2025
Q1 		$340K Buy
176,961
+20,499
+13% +$41.8K ﹤0.01% 2634
2024
Q4 		$297K Buy
156,462
+15,413
+11% +$26.8K ﹤0.01% 2497
2024
Q3 		$186K Buy
+141,049
New +$188K ﹤0.01% 2587
2022
Q3 		– Sell
-862,168
Closed -$304K – 2177
2022
Q2 		$304K Buy
862,168
+677,703
+367% +$284K ﹤0.01% 1866
2022
Q1 		$132K Buy
184,465
+102,691
+126% +$220K ﹤0.01% 2117
2021
Q4 		$185K Buy
81,774
+9,004
+12% +$24.6K ﹤0.01% 2100
2021
Q3 		$210K Buy
72,770
+58,751
+419% +$168K ﹤0.01% 2139
2021
Q2 		$53K Sell
14,019
-25,229
-64% -$84.9K ﹤0.01% 2208
2021
Q1 		$133K Sell
39,248
-160,845
-80% -$579K ﹤0.01% 2143
2020
Q4 		$560K Sell
200,093
-167,193
-46% -$488K ﹤0.01% 1738
2020
Q3 		$922K Buy
367,286
+138,227
+60% +$1.21M ﹤0.01% 1448
2020
Q2 		$3.11M Buy
229,059
+11,936
+5% +$123K 0.01% 964
2020
Q1 		$1.65M Sell
217,123
-80,356
-27% -$625K ﹤0.01% 1147
2019
Q4 		$1.88M Buy
297,479
+207,708
+231% +$987K ﹤0.01% 1292
2019
Q3 		$352K Buy
89,771
+78,575
+702% +$337K ﹤0.01% 1870
2019
Q2 		$54K Buy
+11,196
New +$63.7K ﹤0.01% 2050
2018
Q2 		– Sell
-22,622
Closed -$216K – 2314
2018
Q1 		$216K Sell
22,622
-17,209
-43% -$241K ﹤0.01% 2122
2017
Q4 		$592K Sell
39,831
-11,785
-23% -$195K ﹤0.01% 1859
2017
Q3 		$1.01M Buy
+51,616
New +$794K ﹤0.01% 1666

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AQR Capital Management's AKBA Position: Q2 2026 in Review

AQR Capital Management increased its Akebia Therapeutics (AKBA) stake by 411% in Q2 2026, buying an estimated $8.76M and bringing the position to 9,151,524 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1553.

AQR Capital Management first reported a position in AKBA in Q3 2017 and has held it in 24 quarters since. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • AQR Capital Management held 9,151,524 shares of Akebia Therapeutics worth $10.4M as of Q2 2026.
  • AQR Capital Management bought 7,358,904 Akebia Therapeutics shares in Q2 2026, an estimated $8.76M.
  • Akebia Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1553 holding.
  • AQR Capital Management first reported a position in Akebia Therapeutics in Q3 2017 and has held it in 24 quarters since.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.